The stock price of Aldeyra Therapeutics Inc (NASDAQ: ALDX) has plunged by 0.00 when compared to previous closing price of 5.11, but the company has seen a 2.40% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-12-26 that Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Drug giant AbbVie has a significant option agreement on Aldeyra’s primary pipeline asset that will likely be triggered upon FDA approval in April. An updated analysis around Aldeyra Therapeutics follows in the paragraphs below.
Is It Worth Investing in Aldeyra Therapeutics Inc (NASDAQ: ALDX) Right Now?
Additionally, the 36-month beta value for ALDX is 1.35. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALDX is 57.82M and currently, short sellers hold a 6.13% ratio of that float. The average trading volume of ALDX on January 09, 2025 was 465.57K shares.
ALDX’s Market Performance
The stock of Aldeyra Therapeutics Inc (ALDX) has seen a 2.40% increase in the past week, with a -2.11% drop in the past month, and a -2.67% fall in the past quarter. The volatility ratio for the week is 5.62%, and the volatility levels for the past 30 days are at 6.54% for ALDX. The simple moving average for the last 20 days is 0.93% for ALDX stock, with a simple moving average of 11.33% for the last 200 days.
Analysts’ Opinion of ALDX
Many brokerage firms have already submitted their reports for ALDX stocks, with Oppenheimer repeating the rating for ALDX by listing it as a “Outperform.” The predicted price for ALDX in the upcoming period, according to Oppenheimer is $10 based on the research report published on April 03, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ALDX reach a price target of $10. The rating they have provided for ALDX stocks is “Buy” according to the report published on April 02nd, 2024.
H.C. Wainwright gave a rating of “Buy” to ALDX, setting the target price at $15 in the report published on April 27th of the previous year.
ALDX Trading at 1.51% from the 50-Day Moving Average
After a stumble in the market that brought ALDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.96% of loss for the given period.
Volatility was left at 6.54%, however, over the last 30 days, the volatility rate increased by 5.62%, as shares sank -2.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.04% lower at present.
During the last 5 trading sessions, ALDX rose by +2.40%, which changed the moving average for the period of 200-days by +76.21% in comparison to the 20-day moving average, which settled at $5.06. In addition, Aldeyra Therapeutics Inc saw 2.40% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALDX starting from Machatha Stephen, who sale 16,041 shares at the price of $4.74 back on Aug 12 ’24. After this action, Machatha Stephen now owns 236,771 shares of Aldeyra Therapeutics Inc, valued at $75,975 using the latest closing price.
Greenberg Bruce, the of Aldeyra Therapeutics Inc, sale 10,834 shares at $4.74 during a trade that took place back on Aug 12 ’24, which means that Greenberg Bruce is holding 126,382 shares at $51,313 based on the most recent closing price.
Stock Fundamentals for ALDX
Current profitability levels for the company are sitting at:
- -126.43 for the present operating margin
- 0.52 for the gross margin
The net margin for Aldeyra Therapeutics Inc stands at -114.09. The total capital return value is set at -0.5. Equity return is now at value -43.05, with -33.86 for asset returns.
Based on Aldeyra Therapeutics Inc (ALDX), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.01. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -25.2.
Currently, EBITDA for the company is -35.21 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 743.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.64.
Conclusion
In conclusion, Aldeyra Therapeutics Inc (ALDX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
